A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
← catalyst calendarSponsored by Lixte Biotechnology Holdings, Inc. (industry) · LIXT — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
47estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Apr 2019 | estimated | When the study began enrolling |
| Primary completion | May 2021 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2021 | estimated | The whole study's end, after follow-up |
| First posted | 2019-03-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2019-04-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myelodysplastic Syndromes
Intervention
- Drug: LB-100
Primary outcomes
what the primary-completion date above is the date OFFor Phase Ib - Number of patients with adverse events related to the study treatment as a measure of safety and tolerability of LB-100 study drug
measured From the first dose of the study drug to 30-days following last dose of the study drug
For Phase 2 - Best overall response rate of patients to the study treatment as a measure of efficacy of LB-100 study drug
measured At screening and then at the end of Cycle 3 and Cycle 6. (Each cycle is 21 days)
Permalink · LIXT's whole pipeline · Catalyst calendar · Every registered study · What changed